Amryt Pharma PLC

Amryt Pharma expands exclusive licence agreement for Lojuxta

Rory Nealon, chief operating officer at Amryt Pharma PLC (LON:AMYT), tells Proactive's Andrew Scott they've signed an agreement with Aegerion Pharmaceuticals Inc to significantly expand their exclusive licence agreement for Lojuxta into Russia and the Commonwealth of Independent States, as well as the non-EU Balkan States.

Nealon says there could be up to 450 additional patients in the countries covered by the agreement who could benefit from Lojuxta - which treats a rare life-threatening disorder that causes abnormally high levels of "bad" cholesterol.

Quick facts: Amryt Pharma PLC

Price: £1.23

Market: AIM
Market Cap: £61.97 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...



Amryt Pharma co-founder welcomes 'transformational' Aegerion acquisition

Open Orphan PLC (LON:ORPH) chief executive Cathal Friel co-founded Amryt Pharma PLC (LON:AMYT) along with current CEO Joe Wiley and gives his view on the  acquisition of Aegerion Pharmaceuticals Inc. The merger creates a group with revenues of $136.5mln in 2018 and re-unites the Lojuxta...

2 days, 11 hours ago


Circular to Shareholders

2 days, 13 hours ago

Update on Acquisition of Aegerion

4 days, 5 hours ago

Schedule One

1 week, 3 days ago

Schedule One - Amryt Pharma plc

1 week, 3 days ago

Holdings in Company

1 week, 5 days ago

Holding(s) in Company

2 weeks, 2 days ago

2 min read